Skip to main content
Erschienen in: Psychiatric Quarterly 2/2008

01.06.2008 | Original Paper

Comparison of Clozapine Response for Inpatients in the Research Setting Versus Routine Clinical Practice

verfasst von: Douglas L. Boggs, Deanna L. Kelly, Raymond C. Love, Robert P. McMahon, Robert R. Conley

Erschienen in: Psychiatric Quarterly | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study compares patient characteristics and treatment response between inpatients treated with clozapine in a research setting as compared to those initiated on clozapine during routine inpatient treatment.

Methods

Subjects on clozapine, in clinical trials, were compared with clozapine inpatients receiving routine clinical care.

Results

At baseline, patients in routine clinical practice had more negative symptoms (P < 0.001), activation (P < 0.001) and greater total Brief Psychiatric Rating Scale (BPRS) scores (P = 0.022) than those in the research setting. Routine clinical practice subjects had larger decreases in BPRS total scores (P = 0.042) and positive item scores (P = 0.0005) compared to research subjects. Response to clozapine was observed in 15/85 (18%) research subjects as compared to 60/223 (27%) patients in routine care (P = 0.09).

Conclusions

Patients treated in routine clinical practice have more severe baseline symptoms, but experience significantly greater improvements in psychiatric symptoms.
Literatur
1.
Zurück zum Zitat Clinical development of atypical antipsychotics: Research design and evaluation. Collaborative working group on clinical trial evaluations. The Journal of Clinical Psychiatry 59 Suppl 12:10–16, 1998 Clinical development of atypical antipsychotics: Research design and evaluation. Collaborative working group on clinical trial evaluations. The Journal of Clinical Psychiatry 59 Suppl 12:10–16, 1998
2.
Zurück zum Zitat Hofer A, Hummer M, Huber R, et al.: Selection bias in clinical trials with antipsychotics. Journal of clinical psychopharmacology 20(6):699–702, 2000PubMedCrossRef Hofer A, Hummer M, Huber R, et al.: Selection bias in clinical trials with antipsychotics. Journal of clinical psychopharmacology 20(6):699–702, 2000PubMedCrossRef
3.
Zurück zum Zitat Licht RW, Gouliaev G, Vestergaard P, et al.: Generalisability of results from randomised drug trials. A trial on antimanic treatment. British Journal of Psychiatry 170:264–267, 1997PubMedCrossRef Licht RW, Gouliaev G, Vestergaard P, et al.: Generalisability of results from randomised drug trials. A trial on antimanic treatment. British Journal of Psychiatry 170:264–267, 1997PubMedCrossRef
4.
Zurück zum Zitat Robinson D, Woerner MG, Pollack S, et al.: Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. Journal of clinical psychopharmacology 16(2):170–176, 1996PubMedCrossRef Robinson D, Woerner MG, Pollack S, et al.: Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. Journal of clinical psychopharmacology 16(2):170–176, 1996PubMedCrossRef
5.
Zurück zum Zitat Spohn HE, Fitzpatrick T: Informed consent and bias in samples of schizophrenic subjects at risk for drug withdrawal. Journal of abnormal psychology 89(1):79–92, 1980PubMedCrossRef Spohn HE, Fitzpatrick T: Informed consent and bias in samples of schizophrenic subjects at risk for drug withdrawal. Journal of abnormal psychology 89(1):79–92, 1980PubMedCrossRef
6.
Zurück zum Zitat Woods SW, Ziedonis DM, Sernyak MJ, et al.: Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia. Psychiatric services 51(1):79–84, 2000PubMed Woods SW, Ziedonis DM, Sernyak MJ, et al.: Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia. Psychiatric services 51(1):79–84, 2000PubMed
7.
Zurück zum Zitat Leber PD, Davis CS: Threats to the validity of clinical trials employing enrichment strategies for sample selection. Controlled Clinical Trials 19(2):178–187, 1998PubMedCrossRef Leber PD, Davis CS: Threats to the validity of clinical trials employing enrichment strategies for sample selection. Controlled Clinical Trials 19(2):178–187, 1998PubMedCrossRef
8.
Zurück zum Zitat Patten SB: Selection bias in studies of major depression using clinical subjects. Journal of Clininical Epidemiology 53(4):351–357, 2000CrossRef Patten SB: Selection bias in studies of major depression using clinical subjects. Journal of Clininical Epidemiology 53(4):351–357, 2000CrossRef
9.
Zurück zum Zitat Breier A, Buchanan RW, Kirkpatrick B, et al.: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry 151(1):20–26, 1994PubMed Breier A, Buchanan RW, Kirkpatrick B, et al.: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry 151(1):20–26, 1994PubMed
10.
Zurück zum Zitat Chakos M, Lieberman J, Hoffman E, et al.: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 158(4):518–526, 2001PubMedCrossRef Chakos M, Lieberman J, Hoffman E, et al.: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 158(4):518–526, 2001PubMedCrossRef
11.
Zurück zum Zitat Conley RR, Tamminga CA, Kelly DL, et al.: Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biological Psychiatry 46(1):73–77, 1999PubMedCrossRef Conley RR, Tamminga CA, Kelly DL, et al.: Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biological Psychiatry 46(1):73–77, 1999PubMedCrossRef
12.
Zurück zum Zitat Azorin JM, Spiegel R, Remington G, et al.: A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. American Journal of Psychiatry 158(8):1305–1313, 2001PubMedCrossRef Azorin JM, Spiegel R, Remington G, et al.: A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. American Journal of Psychiatry 158(8):1305–1313, 2001PubMedCrossRef
13.
Zurück zum Zitat Conley RR, Kelly DL: Management of treatment resistance in schizophrenia. Biological Psychiatry 50(11):898–911, 2001PubMedCrossRef Conley RR, Kelly DL: Management of treatment resistance in schizophrenia. Biological Psychiatry 50(11):898–911, 2001PubMedCrossRef
14.
Zurück zum Zitat Lehman AF, Lieberman JA, Dixon LB, et al.: Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 161(2 Suppl):1–56, 2004PubMed Lehman AF, Lieberman JA, Dixon LB, et al.: Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 161(2 Suppl):1–56, 2004PubMed
15.
Zurück zum Zitat Lehman AF, Kreyenbuhl J, Buchanan RW, et al.: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bulletin 30(2):193–217, 2004PubMed Lehman AF, Kreyenbuhl J, Buchanan RW, et al.: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bulletin 30(2):193–217, 2004PubMed
16.
Zurück zum Zitat Miller AL, Hall CS, Buchanan RW, et al.: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. The Journal of Clinical Psychiatry 65(4):500–508, 2004PubMedCrossRef Miller AL, Hall CS, Buchanan RW, et al.: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. The Journal of Clinical Psychiatry 65(4):500–508, 2004PubMedCrossRef
17.
Zurück zum Zitat Stroup TS, McEvoy JP, Swartz MS, et al.: The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin 29(1):15–31, 2003PubMed Stroup TS, McEvoy JP, Swartz MS, et al.: The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin 29(1):15–31, 2003PubMed
18.
Zurück zum Zitat Brambilla P, Barale F, Caverzasi E, et al.: Clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies. International Clinical Psychopharmacology 17(4):189–195, 2002PubMedCrossRef Brambilla P, Barale F, Caverzasi E, et al.: Clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies. International Clinical Psychopharmacology 17(4):189–195, 2002PubMedCrossRef
19.
Zurück zum Zitat Guy W: ECDEU assessment manual for psychopharmacology, revised (DHEW Publication No. ADM 76–338). Rockville, MD, US Department of Health and Human Services, 1976 Guy W: ECDEU assessment manual for psychopharmacology, revised (DHEW Publication No. ADM 76–338). Rockville, MD, US Department of Health and Human Services, 1976
20.
Zurück zum Zitat Slade E, Salkever D: Symptom effects on employment in a structural model of mental illness and treatment: analysis of patients with schizophrenia. The Journal of Mental Health Policy and Economics 4(1):25–34, 2001PubMed Slade E, Salkever D: Symptom effects on employment in a structural model of mental illness and treatment: analysis of patients with schizophrenia. The Journal of Mental Health Policy and Economics 4(1):25–34, 2001PubMed
21.
Zurück zum Zitat Hamilton NG, Ponzoha CA, Cutler DL, et al.: Social networks and negative versus positive symptoms of schizophrenia. Schizophrenia Bulletin 15(4):625–633, 1989PubMed Hamilton NG, Ponzoha CA, Cutler DL, et al.: Social networks and negative versus positive symptoms of schizophrenia. Schizophrenia Bulletin 15(4):625–633, 1989PubMed
22.
Zurück zum Zitat Lysaker P, Bell M: Negative symptoms and vocational impairment in schizophrenia: repeated measurements of work performance over six months. Acta Psychiatrica Scandinavica 91(3):205–208, 1995PubMedCrossRef Lysaker P, Bell M: Negative symptoms and vocational impairment in schizophrenia: repeated measurements of work performance over six months. Acta Psychiatrica Scandinavica 91(3):205–208, 1995PubMedCrossRef
23.
Zurück zum Zitat Kane J, Honigfeld G, Singer J, et al.: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45(9):789–796, 1988PubMed Kane J, Honigfeld G, Singer J, et al.: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45(9):789–796, 1988PubMed
24.
Zurück zum Zitat Krakowski MI, Czobor P, Citrome L, et al.: Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 63(6):622–629, 2006PubMedCrossRef Krakowski MI, Czobor P, Citrome L, et al.: Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 63(6):622–629, 2006PubMedCrossRef
25.
Zurück zum Zitat Meltzer HY, Bastani B, Kwon KY, et al.: A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl) 99 Suppl:S68–S72, 1989CrossRef Meltzer HY, Bastani B, Kwon KY, et al.: A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl) 99 Suppl:S68–S72, 1989CrossRef
26.
Zurück zum Zitat Rosenheck R, Lawson W, Crayton J, et al.: Predictors of differential response to clozapine and haloperidol. Biological Psychiatry 44(6):475, 1998PubMedCrossRef Rosenheck R, Lawson W, Crayton J, et al.: Predictors of differential response to clozapine and haloperidol. Biological Psychiatry 44(6):475, 1998PubMedCrossRef
27.
Zurück zum Zitat Umbricht DS, Wirshing WC, Wirshing DA, et al.: Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. The Journal of Clinical Psychiatry 63(5):420–424, 2002PubMed Umbricht DS, Wirshing WC, Wirshing DA, et al.: Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. The Journal of Clinical Psychiatry 63(5):420–424, 2002PubMed
28.
Zurück zum Zitat Honer WG, Thornton AE, Chen EY, et al.: Clozapine alone versus clozapine and risperidone with refractory schizophrenia. The New England Journal of Medicine 354(5):472–482, 2006PubMedCrossRef Honer WG, Thornton AE, Chen EY, et al.: Clozapine alone versus clozapine and risperidone with refractory schizophrenia. The New England Journal of Medicine 354(5):472–482, 2006PubMedCrossRef
29.
Zurück zum Zitat Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al.: A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. The Journal of Clinical Psychiatry 66(1):63–72, 2005PubMedCrossRef Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al.: A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. The Journal of Clinical Psychiatry 66(1):63–72, 2005PubMedCrossRef
30.
Zurück zum Zitat Lieberman JA, Safferman AZ, Pollack S, et al.: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. American Journal of Psychiatry 151(12):1744–1752, 1994PubMed Lieberman JA, Safferman AZ, Pollack S, et al.: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. American Journal of Psychiatry 151(12):1744–1752, 1994PubMed
31.
Zurück zum Zitat Pickar D, Owen RR Jr, Litman RE, et al.: Predictors of clozapine response in schizophrenia. The Journal of Clinical Psychiatry 55 Suppl B:129–132, 1994PubMed Pickar D, Owen RR Jr, Litman RE, et al.: Predictors of clozapine response in schizophrenia. The Journal of Clinical Psychiatry 55 Suppl B:129–132, 1994PubMed
32.
Zurück zum Zitat Buchanan RW, Breier A, Kirkpatrick B, et al.: Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. American Journal of Psychiatry 155(6):751–760, 1998PubMed Buchanan RW, Breier A, Kirkpatrick B, et al.: Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. American Journal of Psychiatry 155(6):751–760, 1998PubMed
33.
Zurück zum Zitat Iqbal MM, Rahman A, Husain Z, et al.: Clozapine: a clinical review of adverse effects and management. Annals of Clinical Psychiatry 15(1):33–48, 2003PubMedCrossRef Iqbal MM, Rahman A, Husain Z, et al.: Clozapine: a clinical review of adverse effects and management. Annals of Clinical Psychiatry 15(1):33–48, 2003PubMedCrossRef
Metadaten
Titel
Comparison of Clozapine Response for Inpatients in the Research Setting Versus Routine Clinical Practice
verfasst von
Douglas L. Boggs
Deanna L. Kelly
Raymond C. Love
Robert P. McMahon
Robert R. Conley
Publikationsdatum
01.06.2008
Verlag
Springer US
Erschienen in
Psychiatric Quarterly / Ausgabe 2/2008
Print ISSN: 0033-2720
Elektronische ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-008-9067-1

Weitere Artikel der Ausgabe 2/2008

Psychiatric Quarterly 2/2008 Zur Ausgabe

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.